Wenyin Shi, MD, PhD

Medical Director of Radiation Oncology at JHN

Wenyin Shi, MD, PhD


111 South 11th Street
Room G-302, Bodine Center
Philadelphia, PA 19107

Email Wenyin Shi

215-955-0412 fax

Wenyin Shi, MD, PhD

Medical Director of Radiation Oncology at JHN


PhD, University of Florida, Pharmacology - 2002
Shanghai Medical University, China - 1997


University of Florida, Shands Hospital, Gainesville, FL

Most Recent Peer-Reviewed Publications

Research & Clinical Interests

I am a board-certified radiation oncologist who specializes in the treatment of benign brain tumors, primary central nervous system malignancies, brain metastasis, lymphoma, skin cancer, and sarcoma.

I am the medical director of Radiation Oncology at Jefferson Hospital for Neuroscience (JHN), and co-director of the Jefferson Brain Tumor Program. At JHN, we have state of art radiation treatment equipments, and offer full range of radiation treatment for brain tumor patients, including Stereotactic radiosurgery (SRS) with Varian truebeam sTX® and brainlab system, gamma knife, spine SRS, 3D-conformal, and Intensity modulated radiation treatment (IMRT), and volumetric modulated arc therapy (VMAT). I see brain tumor patients along with neurosurgeons, and neuro-oncologists in multidisciplinary brain tumor clinic, where the patients receive comprehensive expert recommendations. I also participate in the institutional and national clinical trials to help bring state-of-the-art cancer care to brain tumor patients at Thomas Jefferson University.

In addition to CNS malignancies, I provide expert care for lymphoma patients. Besides standard radiation treatment for lymphoma patients, I also specialize in total body irradiation (TBI), and total skin electron beam radiation (TSEBT).

I am the Radiation Oncology Director of the Jefferson Cutaneous lymphoma program. I see cutaneous lymphoma patients in multidisciplinary cutaneous lymphoma clinic along with my colleagues from Dermatology and Medical Oncology.

I also provide clinical care for patients with skin cancer, melanoma, and sarcoma.

My research focuses on improving therapeutic ratio for cancer patients. This is achieved through improving patient treatment outcome through innovative clinical trials. My interest is incorporating novel molecular targeting agents into conventional anti-cancer therapy, especially in combination with radiation. My research includes a variety of different new agents, such as anti-angiogenic agents, vascular disrupting agents, signal transduction pathway inhibitors, and immune modulators. I have successfully developed several investigator-initiated clinical trials to evaluate such novel agents with radiation treatment. I also focus on radiation technology improvement with the goal to reduce normal tissue toxicities.